Scorpius Holdings, Inc.
DelistedCIK 1476963fmd_1FZ57MY8TPKJF2CGN5YB6C7Q3MManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2025, 57 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 2 | 6 | 3 | 3 | 2 | 0 | 7 | 6 |
| Total interest income | – | – | – | – | – | – | – | – | – | – |
| Net interest income | – | – | – | – | – | – | – | 1 | – | – |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 3 | 3 |
| Gross profit | – | – | – | – | – | – | – | 0 | 4 | 3 |
| Research and development | 17 | 9 | 8 | 16 | 13 | 13 | 16 | 20 | 20 | 14 |
| Selling, general and administrative | – | – | – | – | – | – | – | 20 | 26 | 22 |
| Total operating expenses | 21 | 13 | 15 | 24 | 24 | 29 | 38 | – | – | – |
| Operating income | (21) | (13) | (13) | (18) | (21) | (26) | (35) | (40) | (42) | (34) |
| Interest expense | 0 | 1 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | 0 | (0) | (0) | (1) | (0) | (1) |
| Income before taxes | – | (13) | (13) | (18) | (20) | (26) | (36) | (42) | (42) | (34) |
| Income tax expense | – | – | (1) | (1) | 0 | – | (0) | (0) | (1) | – |
| Net income from continuing operations | – | – | (12) | (17) | (20) | – | (35) | (41) | (42) | (34) |
| Net income | (20) | (13) | (12) | (16) | (20) | (26) | (35) | (43) | (45) | (33) |